German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation

August 12, 2024 02:08 PM AEST | By Cision
 German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation
Image source: Kalkine Media

BAODING, China, Aug. 12, 2024 /PRNewswire/ -- A landmark German delegation, led by world-renowned stem cell expert Prof. Dato' Sri Dr. Mike Chan, concluded a three-day visit to Baoding, China, marking a significant step in international health cooperation. The visit, from July 11-13, reciprocated an earlier Chinese governmental visit to Germany in June, which focused on collaboration in stem cell research, biotechnology, health, and medical education.

Prof. Dato' Sri Dr Mike Chan stands with delegates from the German Federal Association for Economic Development and Foreign Trade (BWA), City Officials of Baoding, and Sanzang Biotechnology delegates.
Prof. Dato' Sri Dr Mike Chan stands with delegates from the German Federal Association for Economic Development and Foreign Trade (BWA), City Officials of Baoding, and Sanzang Biotechnology delegates.

Prof. Chan, founder of the European Wellness Biomedical Group (EW Group), stands at the forefront of stem cell research. Under his leadership, the EW Group has become a multi-award-winning organization pioneering precursor stem cell therapeutics, immunomodulation, and biological regenerative medicine internationally.

Prof Chan's appointment as a Senator of the German Federal Association for Economic Development and Foreign Trade (BWA) since 2018, plays a crucial role in fostering economic development and foreign trade relations between Germany and key Asian nations. This government-led appointment underscores his international recognition and influence in the field of stem cell research and regenerative medicine in driving cross-border innovations. 

The visit, organized by Michel Schumann, Chairman of the BWA, culminated in the signing of five agreements covering health and educational cooperation, oral medicine, cell therapy technology, medical rehabilitation, and elderly care. Top officials in Baoding, including Municipal Party Committee Secretary Dang Xiaolong, Deputy Secretary and Mayor Yan Jihong, and Meng Qing Yu, vice-president of Hebei University, warmly welcomed the delegates.

During the visit, the German delegation visited schools and a children's hospital. They interacted with students, teachers, and medical staff, promoting careers in biotechnology and medical research. The Chinese officials showed strong interest in Prof. Chan's groundbreaking technology for treating children with special needs, including autism, Down syndrome, cerebral palsy, and global developmental delays.

Prof. Chan's expertise is particularly notable in the field of targeted organ and brain-specific precursor stem cells, having developed over 400 types. Dang Xiaolong emphasized the potential for learning and collaboration between Chinese and German counterparts in this area.

A key symposium facilitated discussions on potential collaborations, with notable participants including Claus Biermann, Director of the Big Health Committee, Sebastian Schutz, General Manager of the German Federal Pharmaceutical Industry Association, and Prof. Ulrich Joos. An MOU on joint stem cell research and education collaboration was signed between the European Wellness Bio Medical Group and San Zang, witnessed by Chinese officials and the German delegation.

With over 50 international patents and authorship of more than 50 books and 100 scientific publications, two of Prof. Chan's notable works include, "Stem Cells in Regenerative Medicine" and "Autism Spectrum Disorder: An Integrative Approach," cement his status as a leading authority in stem cell research and its applications in treating neurodevelopmental disorders.

Currently, Prof. Chan is collaborating with Heidelberg University in Germany on cutting-edge research into neurodevelopmental diseases. This partnership combines his expertise in stem cell therapy with Heidelberg University's renowned medical research facilities, focusing on developing innovative treatments for conditions such as autism, Down syndrome, and cerebral palsy using targeted brain-specific precursor stem cells.

As Germany and China work together to advance medical science and improve healthcare systems, the benefits are expected to impact global health standards and pave the way for further advancements in medical education, stem cell research, and even traditional Chinese medicine.

Dang Xiaolong concluded that the visit culminated in fruitful collaboration between academic and medical institutions, strengthening bonds between both countries and contributing to positive outcomes for both nations. This partnership not only enhances Sino-German relations but also promises significant advancements in treating complex neurological conditions, potentially benefiting patients worldwide.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.